Xerient Pharma Ltd. is focused upon the treatment of pancreatic cancer through novel radiation treatment of the pancreas while protecting the adjacent bowel and stomach organs.

​

Xerient is repurposing an FDA-approved drug that when taken orally, rather than by injection, provides protection to the intestine.

Such protection enables the use of radiation at a level that ensures effective treatment of pancreatic cancer, and potentially other abdominal cancers.